Welcome to UK420

Register now to gain access to all of our features. Once registered and logged in, you will be able to contribute to this site by submitting your own content or replying to existing content. You'll be able to customize your profile, receive reputation points as a reward for submitting content, while also communicating with other members via your own private inbox, plus much more!

This message will be removed once you have signed in.

Dutch Passion

Support forum for Dutch Passion Seeds


537 topics in this forum

    • 270 replies
    • 61 replies
    • 125 replies
    • 319 replies
    • 96 replies
    • 85 replies
    • 0 replies
    • 143 replies
    • 312 replies
    • 81 replies
    • 153 replies
    • 59 replies
    • 2 replies
    • 132 replies
    • 337 replies
    • 17 replies
    • 9 replies
    • 2 replies
    • 2 replies
    • 10 replies
    • 0 replies
    • 3 replies
    • 4 replies
    • 2 replies
    • 11 replies

  • Posts

    • bongme
      Hi   The National Institute for Health and Care Excellence (Nice)    This thing needs to be closed down out of date nonsense    They say it's too expensive? So talk to the government to get it reduced?   Also, the government sell over 45% of the worlds Cannabis Oils Abstraction and they seem to sell it cheap enough to the rest of the world OK!!    To me, this is an Institute for Health and Care very poor excuse so they dont have to deal with oil and it is better than all the pills and creams they have passed over the years Cannabis makes them look stupid!      Load of...    "Moi" By Lolo Zouaï (2019 live studio solo singer)     Bongme 
    • bongme
      Hi   Wee Add On....   Health watchdog rules AGAINST the NHS offering cannabis-based drug Epidiolex to children with rare forms of epilepsy   Daily Mail   Health watchdogs today have ruled against approving a cannabis-based drug for children with rare forms of epilepsy on the NHS. NICE said there was not enough evidence Epidiolex was a cost-effective or that it worked long term.  Epidiolex is almost entirely based on CBD, a compound found in marijuana that is not psychoactive therefore does not give a 'high'. It's proven successful in controlling seizures in children with two forms of epilepsy that are resistant to most treatment - Dravet and Lennox-Gastaut syndromes. But, in draft guidance, NICE couldn't support Epidiolex was an 'effective use of NHS resources'.   Epidiolex is produced by GW Pharma, one of the largest companies in the cannabidiol pharmaceutical market. It is not licensed for use in the UK, unlike the US, but some GPs prescribe it on compassionate grounds, funded by GW Pharma. It is believed Epidiolex has been given to around 150 NHS patients as of March, according to a Government Health and Social Care Committee meeting. Meindert Boysen, director of the centre for health technology evaluation at NICE, said: 'Even though the committee accepted that the evidence shows that cannabidiol with clobazam [an epilepsy drug] reduces seizure frequency, its long-term efficacy is unknown.     Based on the evidence presented to it, the committee could not recommend cannabidiol with clobazam as an effective use of NHS resources.' NICE said the duration of clinical trials on cannabidiol are only 14 weeks, therefore the long-term effects are uncertain. They added that cannabidiol's effectiveness for treating epilepsy could diminish over time, which is seen with other antiepileptic drugs. Professor David Nutt, a neuropsychopharmacologist at the Imperial College London, was not surprised to hear the recommendations. He said: 'Getting pure extracts of plant cannabis products into the NHS now seems a lost cause. 'I have repeatedly argued that medical cannabis isn't suitable for traditional pharmaceutical development programmes in part because of their high costs and low likelihood of returns for investors.   'Another significant issue in the case of these epilepsies is the fact that cannabidiol by itself isn't particularly efficacious. 'Developing and testing such combinations would be extremely challenging and expensive and, given none may ever be reimbursed by NICE, ultimately futile.' Dravet syndrome is a severe form of epilepsy that usually begins within the first year of life, affecting around 600 people in England. Around one in five people with Dravet syndrome will die because of their condition, the majority before 10 years of age. Lennox-Gastaut syndrome is another severely debilitating form of epilepsy diagnosed in childhood, affecting up to 4,000 people in England. Around five per cent of people with Lennox-Gastaut syndrome will die prematurely because of their condition.   Since November 1 last year, specialist NHS doctors can legally prescribe unlicensed cannabis-based products containing THC, which is what makes users 'high'. However, only two patients - both of whom are children - are believed to have been given a prescription on the NHS. Professor Nut said: 'What we need to do now is learn from the parents who have gone overseas to find experts to treat their children and have seen remarkable outcomes. 'At the very least all those children who were hoping for Epidiolex to become available to make their lives better should now have their specialists prescribe medical cannabis for them as a matter of urgency.'   British drugs firm GW Pharmaceuticals also makes Sativex, a cannabis-derived peppermint-flavoured drug in the form of a mouth spray for multiple sclerosis, to ease painful muscle spasms. At £500 a month, it has also been deemed 'too expensive' for the NHS so is rarely prescribed. The draft recommendations are open to comments until 16 September. The next committee discussion is currently scheduled for 26 September before final guidance is expected to be published in November   https://www.dailymail.co.uk/health/article-7384339/Health-watchdog-rules-AGAINST-NHS-offering-cannabis-based-drug-children-epilepsy.html   Add Comments   Bongme 
    • bongme
      hi   Cannabis oil too expensive to prescribe to epileptic children on NHS, advisory body finds   The Telegraph   cannabis drug used to treat children with epilepsy is too expensive to prescribe even though it reduces patients’ seizures, the UK’s medical advisory body has said. The National Institute for Health and Care Excellence (Nice) announced today that it would not recommend cannabidiol combined with anti-seizure drug clobazam for the treatment of two types of severe epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.   Draft guidelines say that while there is evidence that cannabis oil reduces the number of seizures children have, the drug is too expensive and its long-term effects are unclear. Nice was asked by the Department of Health and Social Care to examine whether the cannabis oil drug, used in the United States, should be used in the NHS in England to treat the rare conditions which begin in childhood.   The oil does not contain THC, the psychoactive ingredient that makes cannabis users ‘high’. Nice’s draft guidance, published today, says that while the oil “reduces the number of the main types of seizures associated with these conditions,” the body had “concerns about the validity of the economic models” of GW Pharma, the company that provides it.   The committee said that GW had not explored the possibility of the oil becoming less effective over time, which is the case with other anti-epileptic medication. Nice said that people who currently had access to cannabis-derived drugs to treat epilepsy would not be affected by the lack of recommendation. A limited number of parents have licences to use medical cannabis oils to treat epilepsy, with some resorting to bringing in the medication from abroad in addition to having a valid UK licence. Cannabidiol itself is not licensed for use in the UK but a Nice spokesperson said it expected this to change in the near future.   Professor David Nutt, head of the Centre for Neuropsychopharmacology, Imperial College London, warned that having effective cannabis-derived medication on the NHS may now be "a lost cause" after the lack of recommendation.   A spokeswoman for the Cannabis Patient Advocacy Support Services said the news was “disappointing for parents” and as the oil had in some cases helped children “dramatically”.    https://www.telegraph.co.uk/news/2019/08/22/cannabis-oil-expensive-prescribe-epileptic-children-nhs-advisory/   Bongme 
    • MyDisplayName2000
      Two of them clones look good to go.   In a couple of weeks you can take clones off the clones.